Fig. 4
From: Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition
Activation of IGF1R/p110β/AKT/mTOR produces resistance to BYL719. a Compounds used and their respective targets. b Immunoblots of lysates from parental and resistant cells treated for 24 hours as indicated. c Immunoblots of lysates from parental and resistant cells treated for 24 hours with the respective IC90 concentrations of BYL719 and/or 1 μM of the indicated compounds. d Proliferation of parental and resistant cells treated with the respective IC90 concentrations of BYL719 in combination with 1 μM of the indicated inhibitors. Cell numbers were evaluated using the sulforhodamide B assay. Data are mean ± SEM (n >2, *P <0.05, **P <0.01). DMSO dimethyl sulfoxide, IGF1R insulin growth factor receptor, MCF7p MCF7-parental, MCF7r MCF7-resistant, mTOR mechanistic target of rapamycin, SFK Src family kinases, T47Dp T47D-parental, T47Dr T47D-resistant